Grade 2 oligodendroglioma
The review separates oligodendroglioma from astrocytoma, and grade 2 deferral from definitive treatment.
Disease Pipeline Tools IDH-mutant glioma
IDH-mutant glioma
Programs, trials, and reported response and survival for IDH-mutant glioma.
Standard of care
IDH mutant glioma is not one diagnosis. Treatment depends on astrocytoma versus oligodendroglioma, integrated molecular grade, residual disease, and whether radiotherapy and chemotherapy can safely be deferred. Vorasidenib is an approved postoperative grade 2 option in the setting the review describes. It is not a proven substitute for chemoradiation in aggressive or higher grade disease.
NOT INVESTMENT ADVICE. This is a general evidence review, not individualized medical advice. A line is shown only when the cited review or a trial record in this file states it.
No drugs selected. The grid shows every stated option.
How to read a tile
An empty cell reads “No standard.” The words on the tile carry the status. Border style repeats it.
| Subgroup | Surgery | When radiotherapy and chemotherapy can be deferred | Definitive treatment | Maintenance after treatment | Recurrence |
|---|---|---|---|---|---|
| Grade 2 oligodendrogliomaThe review separates oligodendroglioma from astrocytoma, and grade 2 deferral from definitive treatment. | No standard | ||||
| Grade 2 IDH-mutant astrocytomaVorasidenib is an approved postoperative grade 2 option. It is not a proven substitute for chemoradiation. | No standard | ||||
| Grade 3 oligodendrogliomaThe review names radiotherapy plus PCV as the best established regimen for 1p/19q codeleted grade 3 disease. | No standard | No standard | |||
| Grade 3 IDH-mutant astrocytomaCATNON supports radiotherapy followed by adjuvant temozolomide for non codeleted disease. | No standard | No standard | |||
| Grade 4 IDH-mutant astrocytomaThe review says this is not IDH wildtype glioblastoma, and vorasidenib is not approved for grade 4. | No standard | No standard | |||
| Maintenance record, grade not statedVIGOR names IDH mutant astrocytoma after treatment. SIGMA names maintenance after standard therapy. Neither placement states a grade. | No standard | No standard | No standard | No standard |
The review separates oligodendroglioma from astrocytoma, and grade 2 deferral from definitive treatment.
Vorasidenib is an approved postoperative grade 2 option. It is not a proven substitute for chemoradiation.
The review names radiotherapy plus PCV as the best established regimen for 1p/19q codeleted grade 3 disease.
CATNON supports radiotherapy followed by adjuvant temozolomide for non codeleted disease.
The review says this is not IDH wildtype glioblastoma, and vorasidenib is not approved for grade 4.
VIGOR names IDH mutant astrocytoma after treatment. SIGMA names maintenance after standard therapy. Neither placement states a grade.
No standard
The review separates oligodendroglioma from astrocytoma, and grade 2 deferral from definitive treatment.
Vorasidenib is an approved postoperative grade 2 option. It is not a proven substitute for chemoradiation.
The review names radiotherapy plus PCV as the best established regimen for 1p/19q codeleted grade 3 disease.
No standard
CATNON supports radiotherapy followed by adjuvant temozolomide for non codeleted disease.
No standard
The review says this is not IDH wildtype glioblastoma, and vorasidenib is not approved for grade 4.
No standard
VIGOR names IDH mutant astrocytoma after treatment. SIGMA names maintenance after standard therapy. Neither placement states a grade.
No standard
The review separates oligodendroglioma from astrocytoma, and grade 2 deferral from definitive treatment.
Vorasidenib is an approved postoperative grade 2 option. It is not a proven substitute for chemoradiation.
The review names radiotherapy plus PCV as the best established regimen for 1p/19q codeleted grade 3 disease.
CATNON supports radiotherapy followed by adjuvant temozolomide for non codeleted disease.
The review says this is not IDH wildtype glioblastoma, and vorasidenib is not approved for grade 4.
VIGOR names IDH mutant astrocytoma after treatment. SIGMA names maintenance after standard therapy. Neither placement states a grade.
No standard
The review separates oligodendroglioma from astrocytoma, and grade 2 deferral from definitive treatment.
No standard
Vorasidenib is an approved postoperative grade 2 option. It is not a proven substitute for chemoradiation.
No standard
The review names radiotherapy plus PCV as the best established regimen for 1p/19q codeleted grade 3 disease.
No standard
CATNON supports radiotherapy followed by adjuvant temozolomide for non codeleted disease.
No standard
The review says this is not IDH wildtype glioblastoma, and vorasidenib is not approved for grade 4.
No standard
VIGOR names IDH mutant astrocytoma after treatment. SIGMA names maintenance after standard therapy. Neither placement states a grade.
The review separates oligodendroglioma from astrocytoma, and grade 2 deferral from definitive treatment.
Vorasidenib is an approved postoperative grade 2 option. It is not a proven substitute for chemoradiation.
The review names radiotherapy plus PCV as the best established regimen for 1p/19q codeleted grade 3 disease.
CATNON supports radiotherapy followed by adjuvant temozolomide for non codeleted disease.
The review says this is not IDH wildtype glioblastoma, and vorasidenib is not approved for grade 4.
VIGOR names IDH mutant astrocytoma after treatment. SIGMA names maintenance after standard therapy. Neither placement states a grade.
No standard